SCHEMBL43835

SCHEMBL43835

CCCCCCCCCCCCCCCCOC(=O)CC(O)(CC(=O)OCCCCCCCCCCCCCCCC)C(=O)OCCCCCCCCCCCCCCCC

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.58
RAD52 P43351 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
FAAH O00519 2/20 0.49
DGKA P23743 1/20 0.48
HTR2C P28335 1/20 0.47
EPHX1 P07099 1/20 0.46
TSHR P16473 3/20 0.44
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43
HCAR2 Q8TDS4 1/20 0.42
DNM1 Q05193 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17812511 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA
SCHEMBL42509 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA
SCHEMBL1400502 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA
SCHEMBL579965 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA
SCHEMBL14522676 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA
SCHEMBL1218314 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA
SCHEMBL9410611 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA
SCHEMBL1218319 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA
SCHEMBL2430831 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA
SCHEMBL28058 1.00 NAAA (0.58) NAAARAD52NPSR1FAAHDGKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 730 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315576-B Preparation method of bio-based degradable plasticizer 山东万图高分子材料股份有限公司 2024-08-20 CN claimed
EP-3810135-A1 ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS Poviva Corp. (US) 2021-04-28 EP claimed
EP-3781163-A1 COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF Poviva Corp. (US) 2021-02-24 EP claimed
US-20210045998-A1 TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS Poviva Corp. 2021-02-18 US claimed
WO-2019202396-A1 COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF POVIVA TEA, LLC (US) 2019-10-24 WO claimed
EP-2448433-A2 OMEGA-3 FATTY ACID ENRICHED BEVERAGES Solae, LLC (US) 2012-05-09 EP claimed
EP-2448431-A2 OMEGA-3 FATTY ACID ENRICHED BAKED FOODS AND BAR COMPOSITIONS Solae, LLC (US) 2012-05-09 EP claimed
US-20120107478-A1 Omega-3 Fatty Acid Enriched Baked Foods and Bar Composition SOLAE, LLC (US) 2012-05-03 US claimed
US-20120100257-A1 Omega-3 Fatty Acid Enriched Beverages SOLAE, LLC (US) 2012-04-26 US claimed
CN-102395343-A Absorbent articles comprising wetness indicators PROCTER & GAMBLE 2012-03-28 CN claimed
WO-2011002802-A2 OMEGA-3 FATTY ACID ENRICHED BAKED FOODS AND BAR COMPOSITIONS SOLAE, LLC (US) 2011-01-06 WO claimed
WO-2011002805-A2 OMEGA-3 FATTY ACID ENRICHED BEVERAGES SOLAE, LLC (US) 2011-01-06 WO claimed
EP-1951847-A2 BIODIESEL FUEL COMPOSITIONS HAVING INCREASED OXIDATIVE STABILITY Novus International, Inc. (US) 2008-08-06 EP claimed
US-20080019860-A1 LIQUID MONOPHASIC LIPID-SOLUBLE ANTIOXIDANT COMPOSITIONS AND PROCESSES FOR MAKING THE COMPOSITIONS NOVUS INTERNATIONAL INC. (US) 2008-01-24 US claimed
WO-2008011272-A2 LIQUID MONOPHASIC LIPID-SOLUBLE ANTIOXIDANT COMPOSITIONS AND PROCESSES FOR MAKING THE COMPOSITIONS NOVUS INTERNATIONAL INC. (US) 2008-01-24 WO claimed
WO-2007062304-A2 BIODIESEL FUEL COMPOSITIONS HAVING INCREASED OXIDATIVE STABILITY NOVUS INTERNATIONAL, INC. (US) 2007-05-31 WO claimed
US-20070113467-A1 BIODIESEL FUEL COMPOSITIONS HAVING INCREASED OXIDATIVE STABILITY NOVUS INTERNATIONAL INC. (US) 2007-05-24 US claimed
US-20040180021-A1 Composition comprising at least one film-forming polymer L'OREAL S.A. (FR) 2004-09-16 US claimed
EP-1428494-A1 Mascara comprising filmbuilding polymer and fatty phase L'OREAL (FR) 2004-06-16 EP claimed
WO-2004041220-A2 COMPOSITION CONTAINING A SEMI-CRYSTALLINE POLYMER AND A PASTY FATTY SUBSTANCE L'OREAL (FR) 2004-05-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210045998-A1 TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS LIPA, MMP8, MMP1 NAAA 1359/4885RAD52 3052/4885NPSR1 1437/4885
US-20040180021-A1 Composition comprising at least one film-forming polymer KRT18, CUTA, DSG1 NAAA 3307/4885RAD52 860/4885NPSR1 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.